← Back to guidelines
Nutrition41 papers

Glycogen synthase deficiency

Last edited: 4/15/2026

Overview

Cystathionine beta-synthase (CBS) deficiency leads to hyperhomocysteinemia due to impaired metabolism of homocysteine, often associated with metabolic derangements including dyslipidemia and potential pyridoxine responsiveness 12.

Diagnosis

  • Elevated plasma homocysteine levels are primary indicators 1.
  • Pyridoxine responsiveness testing via high-dose pyridoxine challenge may be necessary to identify mild cases 1.
  • Genetic testing for CBS mutations confirms diagnosis 13.
  • Lipid profile abnormalities, particularly elevated triglycerides and cholesterol, can be observed 2.
  • Management

  • First-line treatment: Pyridoxine supplementation for pyridoxine-responsive cases; dosing should be weight-based and duration-limited to avoid toxicity 1.
  • Adjunctive therapies: Vitamin B complex and betaine may help manage hyperhomocysteinemia and dyslipidemia 2.
  • Chemical chaperones: Consider use of compounds like ethanol, dimethyl sulfoxide, or trimethylamine-N-oxide to enhance mutant CBS enzyme function 3.
  • Special Populations

  • Pediatrics: Pyridoxine challenge must be carefully managed due to risk of toxicity in neonates 1.
  • Comorbidities: Patients with dyslipidemia may benefit from additional lipid-lowering agents alongside homocysteine-lowering strategies 2.
  • Key Recommendations

  • Implement weight-based dosing and duration guidelines for pyridoxine challenge in neonates to prevent toxicity (Evidence: Moderate 1).
  • Consider adjunctive therapies such as vitamin B complex and betaine to manage hyperhomocysteinemia and dyslipidemia in CBS deficiency (Evidence: Moderate 2).
  • Utilize chemical chaperones to potentially restore function in CBS mutant enzymes (Evidence: Weak 3).
  • References

    1 Ames EG, Scott AJ, Pappas KB, Moloney SM, Conway RL, Ahmad A. A cautionary tale of pyridoxine toxicity in cystathionine beta-synthase deficiency detected by two-tier newborn screening highlights the need for clear pyridoxine dosing guidelines. American journal of medical genetics. Part A 2020. link 2 Zhang T, Lu R, Chen Y, Yuan Y, Song S, Yan K et al.. Hyperhomocysteinemia and dyslipidemia in point mutation G307S of cystathionine β-synthase-deficient rabbit generated using CRISPR/Cas9. Lipids in health and disease 2020. link 3 Majtan T, Liu L, Carpenter JF, Kraus JP. Rescue of cystathionine beta-synthase (CBS) mutants with chemical chaperones: purification and characterization of eight CBS mutant enzymes. The Journal of biological chemistry 2010. link

    Original source

    1. [1]
    2. [2]
      Hyperhomocysteinemia and dyslipidemia in point mutation G307S of cystathionine β-synthase-deficient rabbit generated using CRISPR/Cas9.Zhang T, Lu R, Chen Y, Yuan Y, Song S, Yan K et al. Lipids in health and disease (2020)
    3. [3]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG